The Pharmacological Management Of Migraine, Part 2

Preventative Therapy

George DeMaagd, PharmD, BCPS

Continuing Education Credit

After reviewing this article, readers should be able to:

- Define preventative (prophylactic) pharmacotherapy and specify when it may be necessary in the treatment of migraine.
- List the various preventative pharmacotherapies and their role in migraine management.
- Describe the role of the various migraine pharmacotherapies for special populations, including children, pregnant women, and the elderly.
- Describe the general pharmacological treatment pathway for the management of migraine.

This is part 2 of a two-part series.

Introduction

Migraine, its pathophysiology, and abortive (acute) pharmacotherapy were described in Part 1 of this two-part series in the July issue of P&T. Part 2 discusses the role of preventative (prophylactic) pharmacotherapy and the role of migraine treatments in special populations. It also provides an overview and guideline summary for general treatment pathways for the pharmacotherapy of migraine.

Prophylactic Therapy

Preventative migraine therapy refers to the daily administration of drug therapy for various periods, usually three to 12 months. The goals are to reduce the frequency and severity of attacks, to improve and reduce disability, and to minimize or eliminate the need for abortive drug therapy. Patients may be candidates for preventative therapy if they are experiencing two or more migraines per week, if their attacks last more than 48 hours, or if they have ineffective responses or contraindications to abortive therapy. Although numerous medications are used in the management of migraine (Table 1), the commonly used agents that have been studied and that have reported efficacy include the beta blockers, the tricyclic antidepressants, and some anticonvulsants.

Beta-Adrenergic Blockers

Beta blockers were first recognized in the 1960s as effective in migraine prophylaxis; by the 1970s, their use was well established, and they continue to be a treatment of choice. Their mechanism of action is not completely understood, although it may involve modulation of the adrenergic nervous system and an influence on cranial blood vessels.

John Thomas Jefferson University

Jefferson Medical College

Dr. DeMaagd is Professor and Associate Dean of Academic Administration at Union University School of Pharmacy in Jackson, Tennessee.

Accepted for continuing education credit April 10, 2008.

Educational Objectives

After reviewing this article, readers should be able to:

1. Define preventative (prophylactic) pharmacotherapy and specify when it may be necessary in the treatment of migraine.
2. List the various preventative pharmacotherapies and their role in migraine management.
3. Describe the role of the various migraine pharmacotherapies for special populations, including children, pregnant women, and the elderly.
4. Describe the general pharmacological treatment pathway for the management of migraine.

Beta-Adrenergic Blockers

Beta blockers were first recognized in the 1960s as effective in migraine prophylaxis; by the 1970s, their use was well established, and they continue to be a treatment of choice. Their mechanism of action is not completely understood, although it may involve modulation of the adrenergic nervous system and an influence on cranial blood vessels.

John Thomas Jefferson University

Jefferson Medical College

Dr. DeMaagd is Professor and Associate Dean of Academic Administration at Union University School of Pharmacy in Jackson, Tennessee.

Accepted for continuing education credit April 10, 2008.

Beta-Adrenergic Blockers

Beta blockers were first recognized in the 1960s as effective in migraine prophylaxis; by the 1970s, their use was well established, and they continue to be a treatment of choice. Their mechanism of action is not completely understood, although it may involve modulation of the adrenergic nervous system and an influence on cranial blood vessels.

John Thomas Jefferson University

Jefferson Medical College

Dr. DeMaagd is Professor and Associate Dean of Academic Administration at Union University School of Pharmacy in Jackson, Tennessee.

Accepted for continuing education credit April 10, 2008.
Antidepressants

Tricyclic Agents

Although various classes of antidepressants have been studied and used to prevent migraine headache, more data are available for the tricyclic antidepressants (TCAs) (Table 1). Their proposed mechanism of action is thought to involve the inhibition of central cortical depression and sympathetic activity associated with migraine pathophysiology. 

Clinical trials with the TCA amitriptyline have reported a 50% to 70% reduction in the number and in intensity of migraine attacks, with doses ranging from 10 to 100 mg daily. Trials comparing amitriptyline with the beta blocker propranolol have reported similar efficacy. 

The side-effect profile of the TCAs includes dry mouth, constipation, urinary retention, and weight gain along with central effects (sedation, weakness, fatigue, and tremor), which may limit their use in some patients. The secondary-amine TCAs nortriptyline (Pamelor, Mallinckrodt) and desipramine (Norpramin) are considered a drug of choice for migraine prevention, especially in patients without absolute contraindications. They offer an excellent choice for patients with other morbidities, including hypertension and coronary artery disease. Beta blockers should be initiated at low doses along with monitoring of heart rate and blood pressure. An adequate trial of 3 to 12 months with continued assessment of efficacy and tolerability is recommended.

Table 1 Prophylactic Pharmacotherapies for Migraine Headache

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Agent, Dose Range</th>
<th>Monitoring Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta blockers</td>
<td>Propranolol (Inderal)* 40–240 mg/day in divided doses or LA q.d.</td>
<td>Side effects</td>
</tr>
<tr>
<td></td>
<td>Nadolol (Corgard) 20–120 mg q.d. or b.i.d.</td>
<td>• Heart rate</td>
</tr>
<tr>
<td></td>
<td>Timolol (Blocadren)* 20–60 mg q.d. or b.i.d.</td>
<td>• Blood pressure</td>
</tr>
<tr>
<td></td>
<td>Atenolol (Tenormin) 25–100 mg q.d.</td>
<td>• Sexual dysfunction (males)</td>
</tr>
<tr>
<td></td>
<td>Metoprolol (Toprol) 50–200 mg b.i.d.</td>
<td>Drug interactions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Efficacy</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Tricyclic agents</td>
<td>Side effects</td>
</tr>
<tr>
<td></td>
<td>• Amitriptyline 10–150 mg h.s.</td>
<td>• Anticholinergic</td>
</tr>
<tr>
<td></td>
<td>• Nortriptyline (Pamelor) 10–150 mg h.s.</td>
<td>• Cardiac status/predose ECG in some patients</td>
</tr>
<tr>
<td></td>
<td>• Doxepin (Sinequan) 10–200 mg h.s.</td>
<td>• Weight gain</td>
</tr>
<tr>
<td></td>
<td>• Desipramine (Norpramin) 25–150 mg h.s.</td>
<td>Drug interactions</td>
</tr>
<tr>
<td></td>
<td>MAOIs: Phenelzine (Nardil) 15–60 mg t.i.d.</td>
<td>Efficacy</td>
</tr>
<tr>
<td></td>
<td>SSRIs: Fluoxetine (Prozac) 10–80 mg q.d.</td>
<td>Cognitive effects</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Valproic acid (Depakene)* start 250 mg h.s. or b.i.d., titrate dose to 1,500</td>
<td>Side effects</td>
</tr>
<tr>
<td></td>
<td>daily in divided doses</td>
<td>• Sedation/fatigue</td>
</tr>
<tr>
<td></td>
<td>Divalproex sodium 1,000 mg q.d.</td>
<td>• Liver enzymes</td>
</tr>
<tr>
<td></td>
<td>• Depakote valproate sodium</td>
<td>• Complete blood count</td>
</tr>
<tr>
<td></td>
<td>• Depakene solution</td>
<td>Drug interactions</td>
</tr>
<tr>
<td></td>
<td>Topiramate (Topamax)* 100–400 mg b.i.d.–t.i.d. daily</td>
<td>Efficacy</td>
</tr>
<tr>
<td>Calcium-channel</td>
<td>Verapamil (Calan) 240–360 mg daily in divided doses</td>
<td>Side effects</td>
</tr>
<tr>
<td>blockers</td>
<td></td>
<td>• Heart rate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Blood pressure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sexual dysfunction (males)</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Naproxen sodium (Naprosyn) 550–1,100 mg daily in divided doses</td>
<td>Side effects</td>
</tr>
<tr>
<td></td>
<td>Ketoprofen 150 mg daily in divided doses</td>
<td>• Renal function</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Signs and symptoms of bleeding</td>
</tr>
</tbody>
</table>

*These agents are FDA-approved for migraine prophylaxis. 

b.i.d. = twice daily; ECG = electrocardiogram; ER = extended-release; h.s. = at bedtime; LA = long-acting; MAOI = monoamine oxidase inhibitor; NSAID = nonsteroidal anti-inflammatory drug; q.d. = once daily; t.i.d. = three times daily. 

Adapted from references 1, 2, 4, and 34.
pramin, Sanofi-Aventis) may be better tolerated in some patients and may be an additional option. More serious adverse effects include potential cardiac events, such as sinus tachycardia, corrected QT (QTc) prolongation, and blood pressure fluctuations.

Drug interactions involve other central-acting agents, anticholinergic drugs, and serotonergic agents (Table 2). These medications are contraindicated for patients with angle-closure glaucoma, urinary retention, and orthostatic hypotension, which are seen primarily in the elderly. Monitoring in young migraine patients should include efficacy and adverse effects such as weight gain.

Within the antidepressant class, the TCAs are considered a first-line option for preventing migraine in patients who do not have any contraindications. These agents may be an excellent choice for patients with a concurrent comorbidity such as depression, anxiety, or insomnia.

### Anticonvulsant Medications

#### Valproic Acid and Topiramate

The anticonvulsants are another class of medications that have demonstrated efficacy in the prophylaxis of migraine, with valproic acid and topiramate having the strongest evidence to support this indication (see Table 1). The rationale for their use is thought to be related to common mechanisms shared in seizure disorders and migraine involving imbalances between excitatory glutamate activity and gamma-aminobutyric acid (GABA)–mediated inhibition in the brain.

**Valproic acid.** Valproic acid and its derivatives were the first class of anticonvulsants approved for migraine prophylaxis. Trials dating back to the 1980s have been conducted with efficacy reported at variable doses but without a consistent correlation between effective dose and serum levels. Efficacy was described as a reduction in the severity and duration of migraine, with good tolerability reported with titration and individualized doses (see Table 1). Compared with other preventative agents, valproic acid is similar to propranolol in terms of its efficacy and tolerability, as noted with the beta blockers.

Adverse events associated with valproic acid, including central nervous system (CNS) effects (e.g., sedation, tremor, confusion, gastrointestinal problems, and weight gain) may be problematic in some patients. More serious adverse events (e.g., blood dyscrasias, pancreatitis, and liver problems) are rare, but periodic monitoring is required if they occur. Valproic acid and its derivatives should be avoided in women who are planning pregnancy or in women of childbearing age because of the significant risk of teratogenicity with this agent. Drug interactions include other central-acting agents and drugs whose metabolism may be inhibited by valproic acid.

**Topiramate.** The other anticonvulsant that has been studied extensively and has reported efficacy in migraine prophylaxis is topiramate (Topamax) (see Table 1). The drug’s proposed mechanism of action in migraine is probably similar to that of valproic acid, involving GABA-mediated inhibition in the CNS. Although serious adverse effects (kidney stones, myopia with angle-closure glaucoma, sedation, and cognitive changes) can occur, clinical trials reported good tolerability in most patients, especially with lower daily doses. Drug interactions may include other central-acting drugs, antidepressants, and oral contraceptives.

In comparison trials, topiramate was similar to valproic acid and propranolol in terms of efficacy and tolerability. Because of concerns about potential dose-related effects on cognition, patients who are taking topiramate must be monitored regularly, although the drug has excellent clinical utility and can be an option, especially if weight gain is a concern. Migraine patients who take topiramate should be apprised of the drug's potential for visual and cognitive changes and their need to ensure adequate hydration.

**Summary.** Valproic acid and topiramate provide an additional option in the prophylactic treatment of migraine headaches, but adverse effects may limit their use in some patients. Although they are probably considered second-line agents in many cases, they may be excellent choices for patients with a history of seizures disorders; obese patients (especially because of topiramate's weight-loss benefits); or patients for whom beta blockers or antidepressants may be contraindicated.

### Table 2: Common Drugs with Serotonergic Properties

<table>
<thead>
<tr>
<th>Monoamine oxidase inhibitors</th>
<th>Phenelzine (Nardil)</th>
<th>Selegiline (Zelapar, Eldepryl, Emsam)</th>
<th>Isocarboxazid (Marplan)</th>
<th>Tranylcypromine (Parnate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antidepressants</td>
<td>Tricyclics: amitriptyline, others</td>
<td>SSRIs: fluoxetine (Prozac), others</td>
<td>Miscellaneous: nefazodone (Serzone®), trazodone (Desyrel), venlafaxine (Effexor), bupropion (Wellbutrin)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>Buspirone (BuSpar)</td>
<td>Dextromethorphan</td>
<td>Lithium</td>
<td>Amantadine (Symmetrel)</td>
</tr>
</tbody>
</table>

**SSRI =** selective serotonin reuptake inhibitor.

* Serzone has been discontinued, but generic brands are available. Adapted from references 49–53.
Other Anticonvulsant Agents
Small trials with additional anticonvulsant agents reported some benefit with gabapentin (Neurontin, Pfizer) and levetiracetam (Keppra, UCB Pharma), inconsistent findings with zonisamide (Zonegran, Eisai), and a lack of efficacy with lamotrigine (Lamictal, GlaxoSmithKline). Before these agents can be recommended for migraine prophylaxis, additional studies are needed.83–89

Additional Migraine-Prophylactic Agents
Other agents have also been less effective than those discussed earlier, or they need further study. Calcium-channel blockers have had mixed success in migraine prevention,90–94 with a few small trials suggesting modest benefits with verapamil (e.g., Calan, Pfizer) (see Table 1).90–92

Although primarily used in the abortive management of migraine, the nonsteroidal anti-inflammatory agents (NSAIDs) have also demonstrated modest benefits in migraine prophylaxis. Trials with naproxen (Naprosyn, Roche), fenoprofen (Nalfon, Pedinol), tolkenamic acid (e.g., Clotam, Provalis), and ketoprofen reported decreases in duration and severity of migraine. Short-term prophylaxis with NSAIDs in menstrual migraine is discussed in the next column (Special Populations).95–102

Skeletal muscle relaxants, including baclofen (e.g., Lioresal, Novartis) and tizanidine (Zanaflex, Acorda), have been used in the prophylaxis of migraine, but the data are limited. One controlled trial and an open-label trial with tizanidine reported reduced headache frequency, duration, and intensity.103–105

Although more trials are needed, the angiotensin-converting enzyme (ACE)–inhibitors and the angiotensin II receptor blockers (ARBs) have been effective for migraine prevention and may have a future role, especially in patients with cardiovascular comorbidities.106–109

The leukotriene receptor antagonist montelukast (Singulair, Merck) was studied in migraine prevention with mixed results, suggesting that more trials may be needed to clarify its role.110,111 The association of migraine headaches and psychiatric disorders has prompted the consideration of anti-psychotic agents for migraine, and some data have shown benefits with aripiprazole (Abilify, Bristol-Myers Squibb/Otsuka) and olanzapine (Zyprexa, Eli Lilly).112,113

One of the more recent products to be studied in migraine prevention is botulinum toxin type A. Although numerous trials have been conducted, inconsistent findings have been reported, perhaps because of variable trial designs, treatment regimens, or the types of patients studied.114–120

Agents that might also be beneficial for migraine prophylaxis include antihistamines, salmon calcitonin (Miacalcin, Novartis, simvastatin (Zocor, Merck) and clonidine (Catapres, Boehringer Ingelheim).1,4,121 Other potential options include herbal products and supplements such as feverfew (Tanacetum parthenium), butterbur root (Petasites hybridus), co-enzyme Q10, melatonin, riboflavin, and magnesium.122–130

Combination Therapies
Various combinations of prophylactic agents have been used in patients who have not responded to monotherapy. The importance of careful and slow titration of additive agents is essential because of additive side effects, potential toxicities, and drug interactions.

Special Populations
Women. The link between female sex hormones and migraine has been studied extensively. A phenomenon known as menstrual migraine refers to migraine associated with or occurring around a woman’s menstrual cycle. This type of migraine appears to be associated with fluctuations in estrogen levels and the resultant biochemical effects of increased prostaglandins, enhanced prolactin release, and other physiological dysregulation.

Treatment has included a variety of agents, including hormonal manipulation and other therapies administered in conjunction with the menstrual cycle.133–135 The newest concept of treating menstrual migraine is the use of short-term prophylaxis with NSAIDs or triptans starting a few days before the cycle and continuing for about five to seven days.136–140 Refractory cases may respond to estrogen alone or to a combination of progesterone or testosterone in addition to the use of other hormonal manipulations.141–146

Migraine headaches usually improve during pregnancy, but treatment may be required in some patients. Simple analgesics like acetaminophen alone are the drugs of choice. Other therapies can be used with caution and in consideration of the risk–benefit ratio.147–152

Children and adolescents. The prevalence of migraine ranges from 3% to 11% in children younger than 15 years of age. Although more controlled trials are needed for evidence-based treatment of migraine in children and adolescents, the American Academy of Neurology offers some guidance. Options for abortive treatments are simple analgesics alone or triptans. The triptans, including sumatriptan (Imitrex, GlaxoSmithKline), rizatriptan (Maxalt, Merck), and zolmitriptan (Zomig, AstraZeneca), were reported to be safe but not superior to placebo. Fewer data are available for prophylactic treatment in children, although several agents have been proposed.153–159

Elderly Patients. New-onset headache in the elderly is considered a secondary disorder, and a comprehensive evaluation is warranted. As with pediatric patients, the safest agent for the abortive management in older adults is acetaminophen, and the use of the ergots and triptans may be limited if patients have cardiovascular or cerebrovascular disease. The selection of preventative therapies can be determined by concurrent comorbidities or contraindications.160–162

Treatment Plans and Guidelines for Care
As the choices for the pharmacotherapy of migraine expand, clinicians have multiple options to use for both abortive and preventative management. Various guidelines, including those of the U.S. Headache Consortium,4 have recently been revised, although updates are not yet in print.1,2,4,163–165

The available guidelines support the utility of the various pharmacological agents in migraine using a stepped-care approach, with simple analgesics or NSAIDs as first-line choices and stepping up to specific migraine therapies if the response is not sufficient. With the stratified-care approach,
treatment choices are based on the severity of the headache. The Disability in Strategies of Care (DISC) Study provided evidence that using a stratified-care approach might be able to improve headache response and disability time. In this multi-center study, which was conducted in 13 countries, the Migraine Disability Assessment Scale (MIDAS) was used to compare the stratified-care and stepped-care approaches. Patients receiving stratified care were treated according to their MIDAS scores and initially received either aspirin plus metoclopramide (Reglan, Schwarz) or zolmitriptan (Zomig). For the stepped-care group, initial attacks were treated with aspirin and metoclopramide; patients could use a stepped-care strategy during an attack and zolmitriptan therapy with set parameters. Even though the study suggested that the stratified-care approach resulted in improved clinical outcomes, the study’s limitations included an open-label design, a small number of pharmacotherapies, different methods of selecting therapies for the stratified group, and concerns about whether rapid escalation of therapy was comparable to that in clinical practice.

Investigators conducting future trials of stratification might consider other factors, such as symptom profiles, genetics, and biological markers. The present guidelines suggest the use of simple analgesics or NSAIDs for aborting mild-to-moderate migraine and the triptans or possibly the ergots for aborting moderate-to-severe migraines. Considerations for preventive therapy are usually based on the frequency and severity of migraine and other comorbidities, and these approaches may include beta blockers, TCAs, and anticonvulsants.

Conclusion

The pharmacotherapy of migraine is complex. The appropriate use of preventative medications requires an understanding of the various agents available and when they are best used. Part 1, in the July 2008 issue of P&T, reviewed the abortive pharmacotherapy for migraine, the role of these agents, and especially their frequency, which affects the use of preventative therapy.

The management of migraine requires a multidisciplinary approach and calls for physicians experienced in headache management along with nurses, social workers, and pharmacists. The large number of patients experiencing migraine results in significant medication usage and the potential for drug-related problems. Although all health care professionals constitute an important part of the care of the migraine patient, pharmacists can also play a major role by monitoring medication usage, evaluating patients’ responses to therapy, and assessing adverse effects and drug interactions. Pharmacists should also play a prominent part in educating patients about their medications and in providing information on appropriate use.

References


27. van de Ven LL, Franke CL, Koehler PJ. Prophylactic treatment...


Continuing Education Questions for Physicians and Pharmacists

ACPE Program #079-000-08-019-H01-P
Expiration Date: August 31, 2009

TOPIC: The Pharmacological Management of Migraine, Part 2: Preventative Therapy

CME Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Jefferson Medical College and MediMedia USA, Inc.

Jefferson Medical College of Thomas Jefferson University, as a member of the Consortium for Academic Continuing Medical Education, is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. All faculty/authors participating in continuing medical education activities sponsored by Jefferson Medical College are expected to disclose to the activity audience any real or apparent conflict(s) of interest related to the content of their article(s). Full disclosure of these relationships appears on the last page of the article.

Continuing Medical Education Credit

This CME activity is designed to assist physicians and other health care professionals who are P&T committee members in making formulary decisions. Its goal is to increase participants’ ability to recognize and treat important medical problems.

Jefferson Medical College designates this continuing medical education activity for a maximum of one Category 1 credit toward the Physician’s Recognition Award (PRA) of the American Medical Association. Each physician should claim only those credits that he/she actually spent in the educational activity.

This credit is available for the period of one year from the date of publication.

Although forms will be processed when received, certificates for CME credits will be issued every six months, in February and August. Interim requests for certificates can be made by contacting the Jefferson Office of Continuing Medical Education at (215) 955-6992 or by going online to http://jeffline.tju.edu/jeffcme/.

Continuing Pharmacy Education Credit

The Department of Health Policy, Thomas Jefferson University Hospital, is approved by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and complies with the Criteria for Quality for continuing pharmacy education programming. This program (079-000-08-019-H01-P) is acceptable for 1.0 hour of continuing education credit (0.1 CEUs) in states that recognize ACPE-approved providers. Statements of Credit indicating hours/CEUs will be mailed within six to eight weeks to participants who completed this activity and submitted a completed evaluation with payment.

How to Apply for CE Credit

1. Each CE article is prefaced by learning objectives for participants to use to determine whether the article relates to their individual learning needs.
2. Read the article carefully, paying particular attention to the tables and other illustrative materials.
3. Complete the questions and fill in the answers on the evaluation form on the next page.
4. Complete the CE Registration and Evaluation Form. Type or print your full name and address in the space provided, and evaluate the activity as requested. In order for the form to be processed, all information must be complete and legible.
5. Payment of $10 per exam is required for processing and maintenance of records. Make checks payable to P&T®. This processing fee is non-refundable.
6. Send the completed form, answer sheet, and $10 payment to:
   Department of Health Policy
   Thomas Jefferson University
   Attn: Continuing Education Credit
   1015 Walnut Street, Suite 115
   Philadelphia, PA 19107
7. Be sure to mail the Registration, Evaluation Form, and $10 payment within one year of the date of publication. After that date, this article will no longer be designated for credit and forms cannot be processed.
Continuing Education Questions for Physicians and Pharmacists

**TOPIC:** The Pharmacological Management of Migraine, Part 2: Preventative Therapy

**ACPE Program #079-000-08-019-H01-P**

**CE Evaluation:** Select the one best answer to each of the following questions, and record your response on the examination answer sheet. Complete the additional requested information. Forward the answer sheet, with appropriate payment, to the Department of Health Policy, Thomas Jefferson University Hospital, at the address indicated. A certificate of completion will be mailed within six to eight weeks of receipt of your exam/payment. (A minimum test score of 70% is required.)

**Multiple Choice**

Select the one correct answer.

1. As stated in the article, although beta blockers are commonly used for the prophylactic treatment of migraine headaches, of the following four choices, which one is supported by the least amount of scientific data for its use in preventing migraine?
   a. propranolol
   b. timolol
   c. nadolol
   d. atenolol

2. According to the author, which of the following statements regarding the use of beta blockers in the prophylactic management of migraines is not correct?
   a. Beta blockers are effective in approximately 70% of patients.
   b. Beta-1 selective agents, such as atenolol, may be an appropriate option in patients with severe respiratory disease.
   c. Although beta blockers are usually well tolerated, reported side effects may include sedation, dizziness, vivid dreams, depression, fatigue, orthostatic hypotension, and impotence.
   d. Absolute contraindications do not include asthma.

3. Which of the following statements, according to the article, is not correct regarding tricyclic antidepressants (TCAs)?
   a. Clinical trials have reported a 50% to 70% reduction in the number and intensity of migraine attacks.
   b. Trials comparing amitriptyline to the beta blocker propranolol have reported superior efficacy with amitriptyline.
   c. The side-effect profile may include dry mouth, constipation, urinary retention, and weight gain.
   d. Within the antidepressant class, the TCAs are considered a first-line option for preventing migraine in patients without contraindications.

4. Which of the following statements is not correct for the use of anticonvulsant medications for the prophylactic treatment of migraines?
   a. The rationale for their use is thought to be related to common mechanisms shared in seizure disorders and migraine involving imbalances between excitatory glutamate activity and GABA-mediated inhibition in the brain.
   b. Valproic acid and its derivatives were the first class of anticonvulsants approved for migraine prophylaxis.
   c. Compared with other preventatives, valproic acid has demonstrated similar efficacy and tolerability with propranolol, as noted with the beta blockers.
   d. Valproic acid and its derivatives are safe for use in women planning pregnancy or in women of childbearing age.

5. Topiramate could be a first-line therapy for which of the following patients?
   a. patients with a history of seizure disorders
   b. obese patients in particular
   c. patients for whom beta-blockers or antidepressants are contraindicated
   d. all of the above

6. According to the author, other prophylactic agents for migraine may include the following except:
   a. leukotriene receptor antagonists.
   b. calcium-channel blockers.
   c. aldosterone antagonists.
   d. skeletal muscle relaxants.

7. Treatment of menstrual migraine includes the following strategies except:
   a. hormonal therapy administered around the menstrual cycle.
   b. short-term triptan prophylaxis.
   c. long-term progesterone treatment only.
   d. short-term NSAID prophylaxis.

8. Which of the following statements about migraine in children and adolescents is true?
   a. The prevalence in children younger than 15 years of age is 3% to 11%.
   b. Few data are available for prophylactic treatments in children.
   c. Abortive treatment may include triptans or simple analgesics.
   d. all of the above

9. Treatment of migraine in elderly patients may include:
   a. abortive treatment regardless of the patient’s comorbidities.
   b. use of ergots in patients with cardiovascular disease.
   c. abortive treatment with acetaminophen.
   d. use of triptans in patients with cerebrovascular disease.

10. Multiple options exist for abortive and preventative management of migraine. Current guidelines recommend:
    a. combination analgesics for aborting mild-to-moderate migraine.
    b. triptans or ergots for aborting mild-to-moderate migraine.
    c. simple analgesics or NSAIDs for aborting moderate-to-severe migraine.
    d. triptans or ergots for aborting moderate-to-severe migraine.
CE Registration and Evaluation Form

Date of publication: August 2008
Title: The Pharmacological Management of Migraine, Part 2: Preventative Therapy
Authors: George DeMaagd, PharmD, BCPS
Submission deadline: August 31, 2009
ACPE Program #079-000-08-019-H01-P

Registration

Name: ____________________________________________________________ Degree: __________________________________
Street address: ______________________________________________  Last 4 Digits of Social Security No. (Web ID): __________
City: ___________________________________  State: _________  Zip:__________  Telephone:  _____________________________
E-mail Address: _______________________________________   Check one:
I I  Physician  I I  Pharmacist  I I  Other

Time needed to complete this CE activity in hours: I I 0.5 hr  I I 1 hr  I I 1.5 hr  I I 2 hr  I I Other _________________________

Certification: I attest to having completed this CE activity. ___________________________________________________________
Signature (required) Date _______________

Answer Sheet

Please fill in the box next to the letter corresponding to the correct answer

1. a b c d  6. a b c d
2. a b c d  7. a b c d
3. a b c d  8. a b c d
4. a b c d  9. a b c d
5. a b c d  10. a b c d

Evaluation

Rate the extent to which:

<table>
<thead>
<tr>
<th>Very High</th>
<th>High</th>
<th>Moderate</th>
<th>Low</th>
<th>Very Low</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Objectives of this activity were met</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. You were satisfied with the overall quality of this activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Content was relevant to your practice needs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Participation in this activity changed your knowledge/attitudes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. You will make a change in your practice as a result of participation in this activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. This activity presented scientifically rigorous, unbiased, and balanced information</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Individual presentations were free of commercial bias</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Adequate time was available for Q&amp;A</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Which ONE of the following best describes the impact of this activity on your performance:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ This program will not change my behavior because my current practice is consistent with what was taught.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ This activity will not change my behavior because I do not agree with the information presented.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ I need more information before I can change my practice behavior.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ I will immediately implement the information into my practice.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Will you take any of the following actions as a result of participating in this educational activity (check all that apply)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ Discuss new information with other professionals</td>
<td></td>
<td>Consult the literature</td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ Discuss with industry representative(s)</td>
<td></td>
<td>Participate in another educational activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ Other _________________________</td>
<td></td>
<td>None</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Send the completed form and $10 payment (make checks payable to P&T) to: Department of Health Policy, Thomas Jefferson University, Attn: Continuing Education Credit, 1015 Walnut Street, Suite 115, Philadelphia, PA 19107.